Company Encyclopedia
View More
name
Hybribio Biotech
300639.SZ
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support.
1.581 T
300639.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking76/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-12.50%D
    • Profit Margin-75.33%E
    • Gross Margin49.58%B
  • Growth ScoreE
    • Revenue YoY-20.01%E
    • Net Profit YoY-77.36%E
    • Total Assets YoY-15.93%E
    • Net Assets YoY-18.63%E
  • Cash ScoreD
    • Cash Flow Margin-132.75%D
    • OCF YoY-20.01%E
  • Operating ScoreE
    • Turnover0.15E
  • Debt ScoreA
    • Gearing Ratio12.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hybribio Biotech: The company and its subsidiaries have been granted an invention patent for the "live cell sorting microfluidic chip."

    Hybribio Biotech and its subsidiaries have obtained an Australian authorized invention patent, patent number 2024203531, related to "live cell sorting microfluidic chips." This technology can improve the accuracy of cell sorting and does not damage cells during the screening process, having been authorized in multiple regions. This invention aligns with the company's strategic planning, helps to improve the intellectual property system, and enhances core competitiveness

    Zhitong·
    SZ
    300639
    -1.18%
    Zhitong·
    SZ
    300639
    -1.18%

    Hybribio Biotech released its performance for the first three quarters, with a net loss attributable to the parent company of 128 million yuan

    According to the Zhitong Finance APP, Hybribio Biotech released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 486 million yuan, a year-on-year decrease of 20.38%. The net loss attributable to shareholders of the listed company was 128 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 135 million yuan. The basic loss per share was 0.1996 yuan

    Zhitong·
    SZ
    300639
    -1.18%
    Zhitong·
    SZ
    300639
    -1.18%

    Hybribio Biotech: Subsidiary's six respiratory pathogen nucleic acid detection kits have obtained medical device registration certificates

    On the evening of September 29th, Hybribio Biotech announced that its wholly-owned subsidiary, Guangzhou Hybribio Pharmaceutical Technology Co., Ltd., received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for six nucleic acid detection kits for respiratory pathogens. These kits are used for the in vitro qualitative detection of nucleic acids of respiratory syncytial virus, influenza A virus, influenza B virus, adenovirus, parainfluenza virus, and Mycoplasma pneumoniae in nasopharyngeal swab samples

    Zhitong·
    SZ
    300639
    -1.18%
    Zhitong·
    SZ
    300639
    -1.18%

    Hybribio Biotech invests to establish a cultural development company

    According to the Qichacha APP, recently, Chaozhou Kanghe Garden Cultural Development Co., Ltd. was established, with Wang Jianhui as the legal representative and a registered capital of 1 million yuan. The business scope includes: online cultural operations; catering services; food sales; digital cultural creative software development; cultural venue management services; artistic creation; digital advertising production; professional design services; catering management, etc. Qichacha's equity penetration shows that the company is wholly owned by Hybribio Biotech indirectly

    Zhitong·
    SZ
    300639
    -1.18%
    Zhitong·
    SZ
    300639
    -1.18%

    Hybribio Biotech completed the repurchase, spending a total of 50.0198 million yuan to buy back 1.31% of its shares

    According to the Zhitong Finance APP, Hybribio Biotech announced that the company's share repurchase plan has been completed, with a total of 8.4538 million shares repurchased, accounting for 1.31% of the company's total share capital, and the total transaction amount is RMB 50.0198 million (including transaction fees)

    Zhitong·
    SZ
    300639
    -1.18%
    Zhitong·
    SZ
    300639
    -1.18%
    © 2025 Longbridge｜Disclaimer